CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The PrIMAVeRa project aims to combat antibiotic resistance by developing a web-based platform that integrates advanced mathematical models with epidemiological data. This tool will assist healthcare authorities in making informed decisions about prioritizing monoclonal antibodies and vaccines based on their cost-effect…
Antibiotic resistance (AMR), a major threat to human health, is increasing in all bacteria through antibiotic-induced selection, cross-species transfer of genetic mobile elements harbouring resistance genes, global transport and environmental waste.
With an almost empty antibiotic pipeline, monoclonal antibodies (mAbs) and vaccines are increasingly recognized as important tools against AMR.
Yet, available resources cannot finance all potential interventions, and choices need to be made according…
EUROPEAN VACCINE INITIATIVE EV
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Netherlands, Utrecht
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Switzerland, Geneve
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Italy, Verona
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
TECHNICAL UNIVERSITY OF DENMARK DTU
Denmark, Kongens Lyngby
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
